Source comparison
MOTS-c Oral vs Injectable: Administration Comparison
The following table summarizes the fundamental differences between attempting to take MOTS-c orally versus using the clinically validated subcutaneous route. Oral (unprotected) <1% (approaching zero) Stomach (pepsin) and small intestine (pancreatic proteases)
This comparison does not assign a generated winner or score.
- The following table summarizes the fundamental differences between attempting to take MOTS-c orally versus using the clinically validated subcutaneous route.
- Oral (unprotected)
- <1% (approaching zero)
- Stomach (pepsin) and small intestine (pancreatic proteases)
- Not applicable. Insufficient systemic absorption
- None. No published pharmacokinetic data
- Not viable for systemic MOTS-c effects; degraded before absorption
- Sublingual (buccal mucosa)
- Unknown. Likely <5% based on peptide properties
- Salivary enzymes and incomplete mucosal absorption
- Unknown. No published data
- None. No peer-reviewed studies
- Theoretically possible with absorption enhancers, but no evidence supports efficacy
- Subcutaneous injection
- 95–100%
- Minimal. Direct entry to systemic circulation
- 30–90 minutes post-injection
- Extensive. All published MOTS-c research uses injectable administration
- Gold standard route; only method with demonstrated systemic delivery and metabolic effects
- Intravenous injection
- 100% (by definition)
- None. Immediate systemic availability
- Immediate
- Limited to acute research protocols
- Immediate availability but impractical for repeated dosing; subcutaneous preferred for sustained use